当前位置:首页 >财报库 > 报告详情

强生Johnson&Johnson(JNJ)2025年第三季度财报(10-Q)「NYSE」(英文版)(65页).pdf

上传人: 1****1 编号:977747 2025-11-27 65页 453.36KB

下载:

1、UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-Q Quarterly Report Pursuant to Section13 or 15(d)of the Securities Exchange Act of 1934for the quarterly period ended September 28,2025 or Transition Report Pursuant to Section13 or 15(d)of the Securities Exchange Act of 193

2、4for the transition period fromtoCommission file number 1-3215 Johnson&Johnson(Exact name of registrant as specified in its charter)New Jersey22-1024240(State or other jurisdiction ofincorporation or organization)(I.R.S.EmployerIdentification No.)One Johnson&Johnson Plaza New Brunswick,New Jersey 08

3、933(Address of principal executive offices)Registrants telephone number,including area code(732)524-0400 Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12months(or for such sh

4、orter period that the registrant was required to file such reports),and(2)has been subject to such filing requirements for the past 90days.Yes NoIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule405 of Regu

5、lationS-T during the preceding 12months(or for such shorter period that the registrant was required to submit such files).Yes NoIndicate by check mark whether the registrant is a large accelerated filer,an accelerated filer,a non-accelerated filer,a smaller reporting company,or an emerging growth co

6、mpany.See the definitions of“large accelerated filer,”“accelerated filer,”“smaller reporting company,”and“emerging growth company”in Rule12b-2 of the Exchange Act.Large accelerated filerAccelerated filer Non-accelerated filer Smaller reporting company Emerging growth company Ifanemerginggrowthcompan

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
根据《Data》标记内容,以下是全文的简明概括: - **公司概况**:Johnson & Johnson(强生)是一家大型制药和医疗设备公司,总部位于新泽西州。 - **财务数据**: - 截至2025年9月28日,总资产192.8亿美元,总负债113.54亿美元,股东权益79.27亿美元。 - 第三季度净收入5.15亿美元,同比增长21.5%。 - 九个月净收入21.69亿美元,同比增长31.1%。 - **业务板块**:公司分为创新药物和医疗技术两大业务板块。 - 创新药物板块包括肿瘤、免疫学、神经科学、肺高压和传染病等领域。 - 医疗技术板块包括骨科、心血管、糖尿病管理、手术和诊断等领域。 - **风险因素**:包括产品开发、市场风险、产品责任、诉讼和监管活动、战略举措、经济条件、供应链和运营风险等。
**季度财报亮点** **研发投入分析** **市场风险解析
客服
商务合作
小程序
服务号
折叠